• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Primary immune thrombocytopenia: a 'diagnosis of exclusion'?原发免疫性血小板减少症:一种“排他性诊断”?
Blood Coagul Fibrinolysis. 2022 Sep 1;33(6):289-294. doi: 10.1097/MBC.0000000000001144. Epub 2022 Jul 29.
2
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives.难治性原发性免疫性血小板减少症(ITP):当前的临床挑战和治疗观点。
Ann Hematol. 2022 May;101(5):963-978. doi: 10.1007/s00277-022-04786-y. Epub 2022 Feb 24.
3
Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.原发性和继发性免疫性血小板减少症(ITP):是时候重新思考了。
Blood Rev. 2023 Sep;61:101112. doi: 10.1016/j.blre.2023.101112. Epub 2023 Jun 29.
4
Reference guide for the diagnosis of adult primary immune thrombocytopenia, 2023 edition.成人原发性免疫性血小板减少症诊断参考指南,2023 年版。
Int J Hematol. 2024 Jan;119(1):1-13. doi: 10.1007/s12185-023-03672-1. Epub 2023 Nov 13.
5
Current approaches for the diagnosis and management of immune thrombocytopenia.目前免疫性血小板减少症的诊断和治疗方法。
Eur J Intern Med. 2023 Feb;108:18-24. doi: 10.1016/j.ejim.2022.11.022. Epub 2022 Nov 21.
6
Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials.血小板生成素受体激动剂和利妥昔单抗治疗儿童免疫性血小板减少症:前瞻性临床试验的系统评价和荟萃分析
Pediatr Blood Cancer. 2022 Mar;69(3):e29447. doi: 10.1002/pbc.29447. Epub 2021 Dec 28.
7
Diagnosis and treatment of RD in an Australasian cohort with thrombocytopenia.澳大利亚人群中伴有血小板减少的 RD 的诊断和治疗。
Platelets. 2018 Dec;29(8):793-800. doi: 10.1080/09537104.2017.1356920. Epub 2017 Nov 1.
8
Update on diagnosis and treatment of immune thrombocytopenia.免疫性血小板减少症的诊断与治疗进展。
Expert Rev Clin Pharmacol. 2021 May;14(5):553-568. doi: 10.1080/17512433.2021.1903315. Epub 2021 Mar 30.
9
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.依洛尤单抗调节免疫性血小板减少症中单核细胞/巨噬细胞的表型演变和潜在免疫调节作用。
Platelets. 2023 Dec;34(1):2135694. doi: 10.1080/09537104.2022.2135694. Epub 2022 Oct 25.
10
The potential role of thrombopoietin in idiopathic thrombocytopenic purpura.血小板生成素在特发性血小板减少性紫癜中的潜在作用。
Blood Rev. 2002 Mar;16(1):57-9. doi: 10.1054/blre.2001.0184.

引用本文的文献

1
Navigating Primary Immune Thrombocytopenia During Pregnancy: Management Strategies and Considerations: A Comprehensive Review.孕期原发性免疫性血小板减少症的应对:管理策略与注意事项:全面综述
Cureus. 2024 Aug 20;16(8):e67284. doi: 10.7759/cureus.67284. eCollection 2024 Aug.
2
The role of platelet desialylation as a biomarker in primary immune thrombocytopenia: mechanisms and therapeutic perspectives.血小板去唾液酸化作为原发性免疫性血小板减少症生物标志物的作用:机制和治疗前景。
Front Immunol. 2024 Jun 24;15:1409461. doi: 10.3389/fimmu.2024.1409461. eCollection 2024.
3
Recommendations for the management of acute immune thrombocytopenia in children. A Consensus Conference from the Italian Association of Pediatric Hematology and Oncology.儿童急性免疫性血小板减少症的管理建议。来自意大利儿科血液学和肿瘤学会的共识会议。
Blood Transfus. 2024 May;22(3):253-265. doi: 10.2450/BloodTransfus.501. Epub 2024 Jan 29.
4
The Outcomes and Adverse Drug Patterns of Immunomodulators and Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia Egyptian Patients with Hemorrhage Comorbidity.免疫调节剂和血小板生成素受体激动剂在合并出血的埃及原发性免疫性血小板减少症患者中的疗效及药物不良反应模式
Pharmaceuticals (Basel). 2023 Jun 12;16(6):868. doi: 10.3390/ph16060868.

原发免疫性血小板减少症:一种“排他性诊断”?

Primary immune thrombocytopenia: a 'diagnosis of exclusion'?

机构信息

Division of Hematology, University of South Florida, Tamp.

Division of Hematology, Johns Hopkins All Children's Hospital, St. Petersburg.

出版信息

Blood Coagul Fibrinolysis. 2022 Sep 1;33(6):289-294. doi: 10.1097/MBC.0000000000001144. Epub 2022 Jul 29.

DOI:10.1097/MBC.0000000000001144
PMID:35867940
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9415225/
Abstract

Current diagnosis of primary immune thrombocytopenia (ITP) is presumptive, centered on excluding other causes of thrombocytopenia. The diagnosis of ITP is challenging because of the wide range of potential inherited and acquired causes of thrombocytopenia. The treatment of ITP is empiric with steroids, high-dose immunoglobulin, immunosuppressants and thrombopoietin agonists with potential side effects. We searched Medline and Cochrane databases, reviewed the study data and analyzed the individual diagnostic tests for their evidence-based role in the diagnosis of ITP. We then analyzed the strength of the scientific evidence for each diagnostic test in the diagnosis of ITP and identified gaps in the diagnostic accuracy. The diagnostic challenges in ITP include: insufficient evidence for the individual test for diagnosis of ITP, no standardized protocol/guideline for diagnosis, hurdles in accessing the available resources and failure to correlate the clinical data while reviewing the blood smear. We did not identify a diagnostic test that clinicians can use to confirm the diagnosis of ITP. In the absence of a diagnostic test of proven value in ITP, the clinician is best served by a comprehensive history and physical examination, complete blood count and review of the peripheral blood smear in evaluating thrombocytopenia.

摘要

目前原发性免疫性血小板减少症 (ITP) 的诊断是推测性的,主要集中在排除其他血小板减少症的原因上。由于血小板减少症的潜在遗传性和获得性原因范围广泛,因此 ITP 的诊断具有挑战性。ITP 的治疗是经验性的,使用类固醇、大剂量免疫球蛋白、免疫抑制剂和血小板生成素激动剂,可能会有副作用。我们搜索了 Medline 和 Cochrane 数据库,回顾了研究数据,并分析了个体诊断测试在 ITP 诊断中的循证作用。然后,我们分析了每种诊断测试在 ITP 诊断中的科学证据强度,并确定了诊断准确性方面的差距。ITP 的诊断挑战包括:用于诊断 ITP 的个体测试证据不足,缺乏标准化的诊断方案/指南,获取现有资源的障碍,以及在审查血涂片时未能对临床数据进行关联。我们没有发现临床医生可以用来确认 ITP 诊断的诊断测试。在缺乏经证实有价值的 ITP 诊断测试的情况下,临床医生通过全面的病史和体格检查、全血细胞计数以及外周血涂片检查来评估血小板减少症,这对他们最有帮助。